Faculty Profile: Stephen Salloway, MD, MS

Stephen Salloway
Stephen Salloway, MD, MS
Professor of Neurology
Neurology
Work: +1 401-455-6403
My research focuses on the following areas: clinical trials for the prevention and treatment of Alzheimer's disease, mild cognitive impairment, and vascular dementia; studies of genetic and sporadic forms of microvascular brain disease; studies of executive function and frontal behaviors; and the development of imaging biomarkers to study conversion to dementia.

Biography

Stephen Salloway, MD, MS, is Director of Neurology and the Memory and Aging Program at Butler Hospital in Providence, Rhode Island, and Professor of Clinical Neurosciences and Psychiatry at Brown Medical School. He is the Director of the Brown Combined Residency in Neurology and Psychiatry and Codirector of the National Institute on Aging-sponsored Brown Dementia Research Fellowship Program. He received his MD from Stanford Medical School and completed residencies in neurology and psychiatry at Yale University.

Dr. Salloway has published more than 185 scientific articles, book chapters, and abstracts and has edited 3 books. His research focuses on the following areas: clinical trials for the prevention and treatment of Alzheimer's disease, mild cognitive impairment, and vascular dementia; studies of genetic and sporadic forms of microvascular brain disease; studies of executive function and frontal behaviors; and the development of imaging biomarkers to study conversion to dementia. Dr. Salloway has received numerous grants for his research from the National Institutes of Health and from private foundations. He published the first controlled clinical trials of cholinesterase inhibitors for the treatment of mild cognitive impairment and vascular dementia. Under his direction, the Butler Memory and Aging Program has become a nationally recognized clinical research center that tests new disease-modifying treatments for Alzheimer's disease, including amyloid vaccines, gamma secretase inhibitors and modulators, antifibrillization agents, and RAGE inhibitors. His program has also become a key research center in the United States for the study of CADASIL, a genetic disorder that causes stroke and vascular dementia.

Dr. Salloway is a past president of the American Neuropsychiatric Association, a fellow of the American Academy of Neurology, and a member of the American Neurological Association. He is a scientific reviewer for the National Institutes of Health and for more than 30 journals, universities, and research foundations. Dr. Salloway lectures widely on dementia and he is a leading proponent of the early diagnosis and treatment of Alzheimer's disease.

Institutions

Bh

Grants and Awards

1975-1977 Thomas J. Watson Fellow

1981-1985 Roland Jackson Scholar - fellowship support for medical training and research

1984 Rock Sleyster Award -- National AMA Scholarship in Psychiatry

1985 Stanford University Primary Care Program Award for Outstanding Achievement in Clinical Teaching

1985 Stanford Medical School - Honors in Research

1987-1989 American Psychiatric Association Burroughs-Wellcome Fellow

1995 Fellow, Summer Geriatric Research Institute American Association of Geriatric Psychiatry, UC San Diego

1995-6 Surdna Foundation Fellow for Geriatric Research - Brown University

1995 Outstanding Teaching Award - Brown University Department of Psychiatry and Human Behavior

1996 Distinguished Visiting Professor Wilford Hall Medical Center, San Antonio, Texas

1998 Care New England Care Awards Honorable Mention, Butler Hospital Memory Disorders Program

1999 Brown University Honorary Master of Arts Eundem

2000 Fellow, American Neuropsychiatric Association

2001 Outstanding Teaching Award for Undergraduate Medical Student Education, Brown Medical School

2004 Fellow, American Academy of Neurology

2004 Dean's Teaching Excellence Award, Brown Medical School

2006 Dean's Teaching Excellence Award, Brown Medical School

Affiliations

ACADEMIC APPOINTMENTS
1983-1985 Lecturer in Primary Care Internal Medicine, Stanford Medical School

1990-1991 Instructor in Neurology, Yale University School of Medicine

1991-1998 Assistant Professor, Department of Clinical Neurosciences, Brown Medical School

1993-1998 Assistant Professor, Department of Psychiatry and Human Behavior Brown Medical School

1998-2004 Associate Professor; Department of Clinical Neurosciences, Brown Medical School

1998-2004 Associate Professor; Department Psychiatry and Human Behavior, Brown Medical School

2004-present Professor, Department of Clinical Neurosciences, Brown Medical School

2004-present Professor, Department Psychiatry and Human Behavior, Brown Medical School

HOSPITAL APPOINTMENTS
1987-1991 Emergency Psychiatric Privileges, Hospital of St. Raphael, New Haven, CT

1990-1991 Staff Physician, West Haven VA Medical Center

1991-present Director of Neurology, Butler Hospital, Providence, RI

1991-present Neurology Staff, Rhode Island Hospital, Providence, RI

1992-present Co-director, Laboratory for Quantitative Neuroimaging, Butler Hospital

1997-present Director, Butler Hospital Memory and Aging Program

OTHER APPOINTMENTS

EDITORIAL BOARD
1994-present Associate Editor, Journal of Neuropsychiatry and Clinical Neurosciences

1997-2000 Editorial Advisory Board, GeroPsychiatry Report

2004-2007 Editorial Board Applied Neurology

REVIEWER
Journals

Aging and Mental Health, 2006-present

Alzheimer's Disease and Associated Disorders, 2004-present

Alzheimer's and Dementia, 2007-present

American Journal of Geriatric Psychiatry, 2000-present

American Journal of Psychiatry, 2001-present

American Journal of Psychiatry and the Law, 2000-present

Annals of Internal Medicine, 2001-present

Archives of Neurology, 2005-present

BMC Geriatrics, 2007-present

Canadian Journal of Neurological Sciences, 2006-present

CNS Spectrums, 2000-present

Dementia and Geriatric Cognitive Disorders, 2005-present

European Journal of Neurology 2005-present

Expert Opinion-2007-present

International Journal of Psychiatry in Clinical Practice, 2006-present

International Psychogeriatrics, 2006-present

Journal of Affective Disorders, 1997-present

Journal of Clinical Psychiatry, 1997-present

Journal of the American Geriatrics Society, 2007-present

Journal of Geriatric Psychiatry and Neurology, 1998-present

Journal of Neurology, 2006-present

Journal of Neuropsychiatry and Clinical Neurosciences, 1993-present

Medical Letter, 2006-present

Neurobiology of Aging, 1998-present

Neuroepidemiology, 2001-present

Neurology, 2002-present

Neuropsychiatry, Neuropsychology and Behavioral Neurology, 1993-present

Neuropsychopharmacology, 2001-present

New England Journal of Medicine, 2008-present

Psychopharmacology 2003-present

Psychosomatics, 1999-present

Southern Medical Journal, 1998-present

Stroke, 2001-present

Tohoku Journal of Experimental Medicine, 2006-present

National Institutes of Health

National Institute on Aging Neuroscience Branch Ad-hoc grant reviewer, 2001-present

NIMH Advisory Panel "Perspectives on Depression, Mild Cognitive Impairment, and Cognitive Decline," 2003-present

NINDS Genetics of Vascular Cognitive Impairment Study Group, 2004-present

NINDS Special Emphasis Panel ZNS1 SNRB-S, 2004

Adult Psychopathology and Disorders of Aging IRG, February, 2005-present

NINDS Vascular Cognitive Impairment Harmonization Criteria Workshop, April, 2005


Professional Societies, Universities and Research Foundations

Alzheimer's Association and Related Disorders Inc., 1994-present

Alzheimer's Foundation of America Medical Advisory Board, 2003-present

American Academy of Neurology, 1994-present

American Neuropsychiatric Association, 1991-present

American Psychiatric Association, 1993-present

Harvard University Center for Neurodegeneration and Repair External Peer Review Committee, 1999-2004

Institute for the Study of Aging Scientific Review Board, 2003-present

The Michael J Fox Foundation for Parkinson's Disease Research, 2008-present

The New York Academy of Sciences, 1997-present

The Wellcome Trust, 1997-present


Book Publishers

American Psychiatric Press Inc., 1995-present

Cambridge University Press, 1995-present

F.A. Davis Publishers, 1991-present

John Wiley and Sons, 1994-present

Mosby Publishers, 1995-present

Oxford University Press, 1997-present

Swets and Zeitlinger, 1997-present


Internet Sites

WebMD, 2001-present


COLUMNIST

Psychiatric Times- The Aging Brain Column, 1997-present


CONSULTANT FOR DRUG DEVELOPMENT

Hoechst, Marion, Roussel Dementia Advisory Panel, 1997-2002

Eisai, Alzheimer's Disease Program, 1998-present

Bayer, Dementia Advisory Panel, 1998-2003

Novartis Neuroscience, 1999-present

Pfizer Alzheimer's Disease Development Program 1999-present

Consultant, Dementia Research, Janssen Pharmaceutica 2000-present

Sention Inc., Dementia Drug Development, 2002-2005

Sanofi-Aventis Alzheimer's Disease, 2005-present

Elan Alzheimer's Disease, 2007-present

HOSPITAL COMMITTEES

Member, Emergency Medical Committee, Butler Hospital, 1991-1996

Member, Executive Committee, Medical Staff Association, Butler Hospital, 1994-2000


UNIVERSITY COMMITTEES

Member, Stanford Medical School Medical Ethics Committee, 1983-1985

Member, Yale Hillel Medical Ethics Study Section, 1986-1991

Member, Brown University Brain Imaging Center Planning Committee,
1994-1996

Associate Director, Brown University Geriatric Neuropsychiatry

Research and Treatment Program, 1994-present

Member, Brown University Biomedical Computing Committee, 1995-1998

Member, Brown University Geriatric Psychiatry Fellowship Planning Committee, 1997-present

Member, Brown University Psychiatric Residency Curriculum Committee, 1997-present

Member, Brown University Department of Psychiatry Education Committee, 1997-present

Member, Providence VA/Brown University Geriatric Psychiatry Faculty Search Committee, 1997-2000

Member, Brown University Neurology Residency Education Committee, 1998-present

Member, Brown University Greer Professorship/Director of the Division of Geriatric Medicine Search Committee, 1998 -1999

Member, Brown University Psychiatry Residency Research Track Planning Committee, 1998-present

Member, Brown University Surdna Fellowship Review Committee, 1998-present

Reviewer, Royce Fellowship Committee, 2000-present

Member, Brown MRI Research Facility Executive Committee, 2000-present

Co-Director, Brown Department of Psychiatry Imaging Core, 2000-present

Member, Brown Medical School Director of Pediatric Neurology Search Committee, 2001-2002

Member-Departments of Psychiatry and Psychology Research Planning Committee, 2002-present

Member-Steering Committee, Brown Cooperative for Translational Brain Research, 2002-present

Member, Department of Clinical Neurosciences Promotions Committee, 2004-present


NATIONAL COMMITTEES:

Member, Consultation-Liaison Committee, American Psychiatric Association, 1987-1989

Chairman, Scientific Program Committee, American Neuropsychiatric Association, 1993-1995

President, American Neuropsychiatric Association, 1997-1998

Member, Old-Old Depression Research Consortium, 1998-present

Member, International Neuropsychological Society Scientific Program Committee, 2003-4

Member, Data Safety Monitoring Board, Rasgaline for Treatment of Mild-

Moderate Alzheimer's Disease, Eisai Inc., 2004-2005.

Member, Institute for the Study of Aging Working Group on Guidelines for the Treatment of Alzheimer's Disease in the Managed Care Setting in New York City on October 10, 2005

Member, Medical Advisory Board. Alzheimer's Federation of America, 2004-present

Member, Guidelines for the Treatment of Dementia Panel, American

Academy of Neurology, 2006-present

Member, Scientific Advisory Board. CADASIL: Together We Have Hope Foundation, 2006-present

Co-chair, Safety Evaluation Committee, Merck amyloid vaccine trial V950-001, 2007-present

Member, Steering Committee ELND005-AD201–A Phase II, Double Blind, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of Oral ELND005 in Mild to Moderate Alzheimer's Disease. 2008-present.


INTERNATIONAL COMMITTEES:

Member, Advisory Panel, Third International Neuropsychiatry Congress Scientific Program Committee, Kyoto, Japan, 2000, 1997-2000

Member, Eisai/Pfizer International Advisory Board on Vascular Dementia, 2001-present

Member, Executive Committee International Neuropsychiatry Congress Planning Committee,
1998-present

Co Chair: International working group to revise the NINDS vascular dementia criteria for the International Society for Vascular

Behavioral and Cognitive Disorders, 2002-present

Member, International Stroke Society to Develop an Organizing World

Federation Committee for Stroke and Vascular Dementia, 2002-present

Member, Vascular Risk Factors and Dementia: Raising Risk Awareness Study Group, Madrid, Spain, October, 2005.

Member, International CADASIL Study Steering Committee, Eisai, 2005-present

Member, Scientific Program Committee, 3rd Congress of the International Society for Vascular Behavioral and Cognitive Disorders, 2006-present

Member, Dimebon phase 3 Data Monitoring Committee, 2008-present

MEMBERSHIP IN SOCIETIES

2004-present American Neurological Association

2008-present International Society to Advance Alzheimer Research and Treatment

1988-present American Neuropsychiatric Association

1995-7 Associate Director, 1997-8 President, 1993-5 Chair Scientific Program Committee, Member, Committee on Research

1989-present American Academy of Neurology,
Neuroimaging Section, Geriatric Neurology Section
Behavioral Neurology Section

1994-present Society for Neuroscience

1994-present Behavioral Neurology Society

2003-present International College of Geriatric Psychoneuropharmacology

2002-present International Society for Vascular Behavioral and Cognitive Disorders

2000-present American Association of Geriatric Psychiatry Affiliate Member

2004-present International Psychogeriatrics Association

1987-1997 American Psychiatric Association
Consultation - Liaison Committee, 1987-1989

1986-1995 American Medical Association

Funded Research

1. Sleep patterns in people over age 75
National Institute on Aging
$15,000.
1982 – 1983
Role: Principal investigator.
2. A trial of gamma knife anterior capsulotomy to treat refractory obsessive compulsive disorder. A collaborative trial by Brown University, Massachusetts General Hospital and the Karolinska Institute. Jenike M, Rasmussen S. Principal Investigators
1992-present
Role: Investigator assisting with neurological assessment and quantitative imaging analysis.
3. Imitrex post-marketing surveillance study: a multi-center study
Glaxo Pharmaceuticals S2B-350
1994-5
Role: Investigator
4. A multi-center, randomized double-blind, comparative study of gabapentin administered as an initial dosage of 900 mg/day versus a dosage titrated to 900 mg/day over three days.
Parke-Davis Pharmaceuticals 945-090
$3,610.
1994-5
Role: Investigator
5. Subcortical vascular disease in aging
Neurology Foundation Faculty Development Fund
$18,000.
1994-5
Role: Principal Investigator
6. Quantitative MRI analysis of subcortical white matter changes in late-life onset depression
Brown University Department of Psychiatry and Human Behavior Pilot Project Grant.
1992-3-$30,000.
1994-5-$16,000.
Role: Principal Investigator
7. Longitudinal course of subcortical cerebrovascular disease in late-life depression: an MRI follow-up study. Jenkins M-PI
Butler Hospital Faculty Research Fund
$25,000.
1995-6
Role: Co-investigator
8. Subcortical vascular disease in geriatric hypertension
Surdna Foundation Fellowship for Research in Gerontology
$15,000.
1995-6
Role: Principal Investigator
9. Cognex: neuropsychiatric testing and assessment of caregiver time
Parke-Davis Pharmaceuticals 970-87
$2,000
1996-7
Role: Investigator
10. Vascular predictors of depression and cognitive impairment in the elderly.
Brown University, Dept. of Psychiatry and Human Behavior Pilot Project Grant
$20,000
1996-7
Principal Investigator
11. Effect of pemoline on measures of attentional performance in adult ADHD
Abbott Laboratories
$4,000
1996-7
Principal Investigator
12. An open-label trial of donepezil for the treatment of Alzheimer's disease
Pfizer/Esai Pharmaceuticals E2020-A001-313
$22,500
1996-7
Co-Principal Investigator
13. Neuropathological, neuroimaging and neuropsychological features of CADASIL.
American Heart Association Grant-in-Aid 9706211S
$20,000
1997-9
Principal Investigator
14. An eight-week, parallel group, double-blind, placebo-controlled study of sertraline in elderly outpatients with DSM-IV major depression. Martin Keller-PI
Pfizer Pharmaceuticals R-0552
$71,000
1997-8
Brown site administrator, Co-investigator
15. Relationship of MRI hyperintensities to treatment response in geriatric depression.
Pfizer Pharmaceuticals R-0552 MRI study
$150,000
1997-2000
Principal Investigator with Ranga Krishnan, M.D. of Duke for this multi-center study
16. Metrifonate Nationwide Investigational Trial
Bayer Pharmaceuticals D-97-019
$10,000
1997-8
Principal Investigator
17. A 24 week, multi-center, randomized, double-blind, placebo-controlled evaluation of
the efficacy and safety of donepezil hydrochloride (E2020) in patients with dementia associated with cerebrovascular disease. Eisai Inc. E2020-A001-307
$ 130,000
1998-2001
Principal Investigator, Brown site
18. A multi-center, double-blind comparison of efficacy and safety of Seroquel, haloperidol, and placebo in the treatment of elderly subjects residing in nursing homes or assisted care facilities and Presenting with Alzheimer's dementia and psychoses or other selected psychoses.
Zeneca Pharmaceuticals 5077IL/0039
$120,000
1998-9
Investigator and administrator of the Brown site
19. A randomized, double-blind, placebo-controlled trial of citalopram in depressed patients at least 75 years of age.
Forest Laboratories CIT-MD3-97-03-000
$130,000
1998-
Investigator, Brown site administrator
20. Subcortical microvascular disease in geriatric depression
National Institute of Mental Health 1 K08 MH01487
$752,994
1999-2004
Principal Investigator
21. A 24-week, multicenter, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride in subjects with mild cognitive impairment.
Eisai E2020-A001-401
$110,000
1999-2000
Co-Principal Investigator with Paul Malloy, Ph.D.
22. A multi-center, randomized, double-blind, placebo-controlled trial of estrogen to prevent Alzheimer's disease in women at risk.
National Institute on Aging RO 1AG15922/Columbia University
$146,000
1999-2003
Principal investigator, Brown site
23. Combined behavioral and pharmacological intervention to improve memory in Alzheimer's disease
Alzheimer's Association Investigator Award (Deborah Cahn-Weiner PI)
$80,000
1999-2001
Consultant
24. Improving sleep and cognitive functioning in Alzheimer's disease
Eisai/Pfizer Investigator Award (Mark Aloia PI)
$100,000
1999-2001
Investigator
25. Genetic Models of Human Dementia
P20 RR15578-01 (a project of the Brown Center for Genetics and Genomics COBRE total grant $11,219,863)
$1,013,374
2000-2005
Co-Principal Investigator (Justin Fallon, subproject PI)
26. Heart Disease, CNS Dysfunction and Outcome in the Elderly
NIH 1050258905
$1,753,134 (Ronald Cohen, PI)
2000-2005
Investigator
27. A randomized double blind placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment clinically at risk for development of clinically probable Alzheimer's disease.
Janssen GAL-INT-11
$300,000
2001-4
Principal Investigator
28. A randomized, 30-week. double-blind, placebo-controlled trial to evaluate the safety and efficacy of galantamine in the treatment of dementia secondary to cerebrovascular disease
Janssen Research Foundation GAL-INT-26
$125,000
2001-3
Principal Investigator
29. Functional impairment in Alzheimer's disease and normal aging
National Institute on Aging
AG05898-01 (Patricia Boyle, PI)
$60,000
2000-2
Consultant/Investigator
30. Treatment of apathy in Alzheimer's disease
Alzheimer's Association, (Patricia Boyle, PI)
$100,000
2001-3
Consultant/Investigator
31. Electrical stimulation of the internal capsule for intractable OCD and depression (Ben Greenberg, P.I.)
Medtronics
2001-present
Investigator assisting with neurological assessment and quantitative imaging analysis
32. A double-blind, randomized pilot study to evaluate the effects of galantamine and donepezil on sleep and attention and GI tolerance in patients with mild-moderate Alzheimer's disease
Janssen Pharmaceutica
$100,000
2002-
Principal Investigator
33. A telephone intervention for dementia caregivers
NIMH R21 MH62561, (Geoffrey Tremont, PI)
$576,042
2002-5
Consultant/Investigator
34. An 80-week, randomized, multi-center, parallel-group, double-blind study of the efficacy and safety of atorvastatin 80 mg plus an acetylcholinesterase inhibitor versus an acetylcholinesterase inhibitor alone in the treatment of mild to moderate Alzheimer's disease (Protocol # A2581078)
Pfizer, Inc.
2003-5
$274,240
Principal Investigator
35. NIA ZAG1 FAS-5 J1 Institutional National Research Service Award
Dementia Research Fellowship T-32 (Paul Malloy, PI)
$1,492,665
2003-2008
Description: Dementia research fellowship for 2, 2-year post-docs in 2003 increasing to 4 2-year positions.
co-PI with Richard Besdine
36. A 24-week, multi-center, randomized, double-blind, placebo-controlled evaluation of the efficacy, safety and tolerability of donepezil hydrochloride (E2020) in patients with dementia associated with cerebrovascular disease (Protocol # E2020-A001-319)
Eisai Medical Research, Inc.
2003-
$81,336
Principal Investigator
37. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of Titration and Treatment with C105 in Subjects with Mild Cognitive Impairment (MCI) (Protocol # 22020)
Sention Inc.
2003
$157,400
Co-Principal Investigator
38. Efficacy and Safety of LY451395 in Patients with Probable Alzheimer's Disease
(Protocol #H6N-MC-LEAM)
Lilly Pharmaceuticals
2003
$101,856
Principal Investigator
39. Working memory and frontal white matter integrity in mild cognitive impairment
Alzheimer's Association (Stephen Correia, Ph.D., PI)
NIRG-03-6195
2003-5
$100,000
Mentor and investigator
40. An open-label, multi-center, one-year extension of the evaluation of donepezil hydrochloride (E2020, Aricept®) in patients with dementia associated with cerebrovascular disease (Protocol # E2020-A001-320)
Eisai Medical Research, Inc.
2003-2005
$62,964
Principal Investigator
41. A 51 week, , multicenter, randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil hydrochloride (E2020) in subjects with mild cognitive impairment (Protocol # E2020-A001-412)
Eisai Medical Research, Inc.
2004-
$128,832
Principal Investigator
42. Galantamine ER open label rapid dose escalation trial in Alzheimer's disease
(Protocol # GAL-ALZ-303)
Janssen Pharmaceutica Products, L.P.
2004-2005
$32,000
Principal Investigator
43. A double-blind, phase II, safety and efficacy evaluation of ONO-2506PO in patients with mild to moderate Alzheimer's disease (Protocol ONO-2506POU010)
Ono Pharmaceutical Co., Ltd.
2004-
$214,890
Principal Investigator
44. A phase III study of the efficacy and safety of Alzhemed™ in patients in mild to moderate Alzheimer's disease (Protocol CL-758007)
Neurochem, Inc.
2004-
$462,000
Principal Investigator
45. An open-label, 8-week clinical trial of the safety and efficacy of Escitalopram for the treatment of depression and anxiety in dementia caregivers
Forest Laboratories
2005-
$106,111
Principal Investigator
46. Aging Brain: DTI, Subcortical Ischemia and Behavior
1 R03 AG023916-01A1
2005-2007
$120,000
Principal Investigator
47. Metrics for Quantifying White Matter Variation: Image Analysis, Testing and Application
Brown Vice-President Seed Grant
2005-6
$100,000
David Laidlaw, PI (Co-Investigator)
48. Treatment of apathy in Alzheimer's disease with modafinil
1 F32 MH075583-01
2005-2007
Laura Frakey, Ph.D., PI, (co-mentor with Dr. Malloy)
49. Phase 3 Multi Center, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognitive and Global Function in Subjects with Mild to Moderate Dementia of the Alzheimer's Type (MPC-7869-04-005.03)
Myriad Pharmaceuticals, Inc.
2005-
$161,772
Principal Investigator
50. A Phase IIa Multicenter, Randomized, Double-Blind, Placebo Controlled, Multiple Ascending Dose, Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Trial of AAB-001 (ELN116727) in Patients with Mild to Moderate Alzheimer's Disease (AAB-001-210)
Elan Pharmaceuticals, Inc
2005-
$196,482
Principal Investigator
51. A Phase I, Multicenter, Randomized, Blinded, Single Ascending Dose, Safety, and Tolerability Trial of ACC-001 (QS-21) in Patients with Mild to Moderate Alzheimer's Disease (ACC-001-10)
Elan Pharmaceuticals, Inc
2005-
$181,454
Principal Investigator
52. A Double-Blind Placebo-Controlled Study of VP4896 For The Treatment Of Mild-To-Moderate Alzheimer's Disease (VP-AD-301)
Voyager Pharmaceutical Corporation
2005-
$276,000
Principal Investigator
53. Alzheimer's Disease Neuroimaging Initiative ADNI-024
NIA U01 AG10483
2006-
$330,825
Principal Investigator
54. An 18 Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment.
Eisai
2005-6
$160,000
Principal Investigator, Steering Committee Member, assisted with study design
55. A 54' week, double-blind, randomized, placebo-controlled, parallel-group study to investigate the effects of rosiglitazone (extended release tablets) as adjunctive therapy to donepezil on cognition and overall clinical response in APO €4-stratified subjects with mild to moderate Alzheimer's disease
Glaxo Smith Kline
2006-
$250,000
Principal Investigator
56. Inter-rater reliability between expert and non-expert-physicians in the diagnosis of amnestic MCI in the community setting A2501051/E0000-A001-001
Pfizer, Eisai
2006-
$23,000
Principal Investigator, Consensus Committee Member
57. A phase IIa, multicenter, randomized multiple ascending dose, safety, tolerability and immunogenicity trial of ACC-001 with QS-21 adjuvant (amyloid vaccine trial) in patients with mild to moderate Alzheimer's Disease
Wyeth ACC-001 3134K1-2201
2007-present
$790,649
Principal Investigator
58. Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer's Disease
Eisai
2007-present
$140,000
Principal Investigator

Teaching Experience

HOSPITAL AND UNIVERSITY TEACHING ROLES
1980-1981 University of California Berkeley
Teaching Assistant for the course: Human Growth and Development for medical and graduate students.
1983-1985 Stanford Medical School
Coordinator of the psychiatry and behavioral science curriculum in the Primary Care Program
Instructor for the course: Introduction to Clinical Medicine
1989-1991 Yale University
Director of the course: Behavioral Neurology - for medical students Seminar
Director: Neuroradiology/Clinical Correlations for the psychiatry housestaff and attending staff at Yale-New Haven Hospital
Co-director of the bi-weekly Movement Disorder seminar at Yale University
Instructor for the neurology section in The Introduction to Clinical Medicine Course for Medical Students
1990-1995 Yale University
Co-director of the course: Comprehensive Review of Neurology
Offered 2 times per year
1991-present Brown University
Undergraduate Education
Director of an Independent Study Course in neurobehavioral research for undergraduates majoring in neuroscience and biology (B195/196) (1-3 students per semester, includes honors thesis for eligible seniors).
Lisa Israeli, Neuroscience, fall and spring semesters 1994-5 and 1995-6.
Project: Development of a brain imaging rating scale. Co-author of one peer reviewed paper and one abstract.
Kathy Chang, Neuroscience, spring 1994-95, fall 1995-96.
Project: Clinical profiles of adults presenting with attentional disturbance. Honorable mention for the ANPA Young Investigator Award for abstract #12 at the American Neuropsychiatric Association Annual Meeting 1995.
Mary Lynn Mercado, Biology, spring 1994-95, fall and spring semesters 1995-96. Senior honors thesis: Subcortical vascular disease and late-life depression
Joseph Hong, Neuroscience, spring semester 1995-96, University Teaching and Research Assistant (UTRA) summer 1996, fall, spring 1996-97 Projects: I. Effect of pemoline on cognitive performance, II. Honors thesis. MRI and small artery changes in CADASIL and Binswanger's disease. Author of two peer-reviewed papers and Presentation at two national meetings
Jorge Intal, Neuroscience, summer 1996, fall, spring 1996-97
Project: Cerebral microvascular disease in aging: I. A comparison of FLAIR and PD MRI sequences and II. MRI-autopsy correlation of signal hyperintensities. Presented at the Society for Neuroscience 27th Annual Meeting, New Orleans (abstract #21).
Maureen Cruz, Biology, fall 1997
Project: Cerebral perfusion abnormalities in normal pressure hydrocephalus.
Mary Pan, Neuroscience, fall and spring 1998-9
Project: Neuropsychiatric symptoms in vascular dementia
Susan Rymer, Anthropology, fall and spring 1999-2000
Project: Awareness of cognitive deficit in Alzheimer's disease and caregiver burden
Tamar Gur, Biology Honors Thesis second reader, 1999-2000
Project: ApoE4 and agrin staining of microvascular integrity in Alzheimer's disease (co-mentor with Dr. Stopa)
Ellen Kotwas, spring 1999-2000, summer and fall 2000-2001
UTRA Fellow, Psychology Honors Thesis
Project: Affective and semantic priming in Alzheimer's disease
Awarded the Muriel Fain Sher Premium in Psychology by the Department of Psychology for her honors research (co-mentor with Dr. Heindel)
Audrey Kwak, 2001-2, Psychology Honors Thesis
Project: Predictors of functional impairment in Alzheimer's disease
Leah Belsky, 2001-2 Biology
Project: When familial FTD is suspected: Ethical and clinical issues in genetic research
Sophie Desbiens, Summer 2002 Brain Science UTRA Fellow
Project: Development of an assay for notch-3 mutations
Suzanne Drodge, Summer 2002 MRI Research Facility UTRA Fellow
Project: Diffusion tensor imaging in CADASIL
Stan Pelosi, Summer 2002 PLME summer research assistantship
Project: Working memory in Alzheimer's disease (co-mentor with Dr. Malloy)
Jonathan Greer, 2003 PLME summer research assistantship
Project: A PCR-SSCP reliant assay for notch-3 mutations in CADASIL patients
Irmak Turan, Barrington High School Senior Project (awarded honors)
Project: Is Down's syndrome a good genetic model for studying Alzheimer's disease?
Ryan Li, 2003-4 Neuroscience honors thesis
Project: MRI correlates of ambulation and motor functioning in Alzheimer's disease.
Thea Brennan-Krohn, 2004 Summer Training in Aging Research Topics Mental Health- NIMH Award- Diffusion tensor imaging and working memory in SIVD. 2005 Summer Training in Aging Research Topics Mental Health NIMH Award- Molecular analysis of notch and notch ligand expression in vascular dementias
Christopher Song, 2004 Summer Training in Aging Research topics Mental Health- NIMH Award
Project: Development of an assay for notch3 mutations
Sharon Song, 2007 Biology concentrator honors thesis (co-mentor with Stephen Correia, PhD)
Project: MOCA is more sensitive than MMSE in MCI because of executive dysfunction..
Brown Medical Student Education
Director of the second semester, first year course. The Human Brain and Behavior (Biomed 370)
Co-leader of a small group and lecturer in the Neurologic Pathophysiology Course for second year students (Neurosciences 262)
Director, Neuropsychiatry and Behavioral Neurology Elective (Biomed 515)
Extended Medical Student Research Elective
Ximena Morales, 1994-95, Medical School Columbia, South America, six month neurobehavioral research elective in geriatric depression
Shirine Nassery, PLME summer research assistantship 2001
Relationship of subcortical microvascular changes in Alzheimer's disease to ApoE genotype and systolic hypertension
Risha Kopel, summer research project 2001
Use of diffusion tensor MRI to differentiate normal pressure hydrocephalus from Alzheimer's disease
Tyler Berzin, 2001-2, Brown Faculty Scholars Award recipient
Microvascular changes in Alzheimer's disease (co-mentor with Dr. Stopa)
Ari Blitz, 2000-1, Brown faculty Scholars recipient
Alterations in frontal-subcortical circuits in OCD
Ainsley MacLean, 2002 PLME summer research assistantship
Phenotypic variation in a large family with CADASIL, Recipient of an Alzheimer's Association Travel Award to present her work at the 8th World Alzheimer's Disease Congress in Stockholm, 7/2002
Colleen Craig 2005 3rd year medical student 6 month longitudinal neurology elective
Michael Joseph, Summer 2005, Clinical Neuroscience Mental Health Research Training-R25 MH 60477-05 Relationship of hippocampal and whole brain volume to cognitive impairment in CADASIL
James Enos, 2008 Summer Training in Aging Research Topics Mental Health NIMH Award, Normal pressure hydrocephalus: clinical-pathological correlations. primary mentor with Dr. delaMonte.
Brown Post-graduate Medical Education
Director of the American Board of Psychiatry and Neurology/ACGME-Approved 855-43-44-005 Brown University Combined Residency Training Program in Neurology and Psychiatry.
NIA ZAG1 FAS-5 J1 Institutional National Research Service Award
Dementia Research Fellowship T-32 (Paul Malloy, PI) 2003-2008, co-PI with Richard Besdine
Director of the Neuropsychiatry/Behavioral Neurology Fellowship
Director of the Neuropsychiatry Track in the Psychiatry Residency
Neurology Ward and Consultation Service Attending - Rhode Island Hospital
Neurology Consultation Service Attending - Butler Hospital
Behavioral Neurology Outpatient Elective Rotation Attending
Mentor, Brown Psychiatry Residency Research Track
Lecturer in the Brown University Neuropsychology Training Seminar
Lecturer in the weekly neurology resident seminar series
Lecturer in the Geriatric Psychiatry and Geriatric Medicine fellowship programs
Lecturer on Geriatric research in the Brown University NIH T-32 Young Investigator
Training Seminar
Director of the Brown University Neuropsychiatry/Behavioral/Neurology Grand Rounds Series- Butler Hospital
Co-director of Brown University Neuroradiology Rounds – Butler Hospital.
Brown Medical School Extended Resident Electives
Cleve Shirey, M.D. Senior Psychiatry Resident, 1993-4, Year-long one-half day weekly neuropsychiatry outpatient continuity clinic
Suda Bakshi, M.D. Triple Board Resident in Pediatrics, Child Psychiatry and Adult Psychiatry, 1994-5, Nine month one-half day weekly neuropsychiatry outpatient clinic
Jeffrey Daly, M.D.Senior Psychiatry Resident, 1994-5, Twelve month, part-time elective in neuropsychiatric research. Published two peer-reviewed articles and one book chapter and was selected for the American Psychiatric Association Burroughs-Wellcome Award.
Neeta Jaine, M.D. Senior Psychiatry Resident, 1995-6, Four month weekly neuropsychiatry outpatient continuity clinic
Ron Neeper, M.D., Ph.D., Triple Board Resident in Pediatrics, Child Psychiatry and Adult Psychiatry and Pediatric Neurology Resident 1994-6, Two year neuropsychiatry continuity clinic two half-days/week
Gary Epstein-Lubow, M.D., Senior Psychiatry Resident, Four month weekly neuropsychiatry outpatient elective 2001, Project-Neuropsychiatric aspects of NPH
Combined Residents in Neurology and Psychiatry
Curt LaFrance, M.D., 1995-2001
Current position: NIMH Research Fellow at Rhode Island Hospital. Recipient of a NINDS Career Development Award 2003-8.
Rochelle Woods, M.D., 1999-present
Research project: Validating a scale for measuring outcome from intracerebral hemorrhage.
Neuropsychiatry Fellows
John Campbell, M.D., 1992-1993
Published two peer-reviewed papers and made two Presentations at national meetings during the fellowship. Current Position-Director of Neuropsychiatry, Henry Ford Hospital, Detroit, MI
Colin Harrington, M.D., 1996-97
Current position-Director of Consultation-Liaison Psychiatry, Rhode Island Hospital. Dr. Harrington received the 2003 Senior Citation Award for best faculty mentorship from the 2003 Brown Medical School graduating seniors.
T-32 Post-Doctoral Research Fellows
Stephen Correia, Ph.D., 2003-2005
Working memory and frontal white matter integrity in mild cognitive impairment (mentor)
Gary Lubow, M.D., 2003-2005
Treatment of depression in dementia caregivers (co-mentor with Van Miller, Ph.D.)
Visiting Scholars
Paul O'Hara, M.D., 1998-2000, University of Western Australia
Research supervisor, Controlled treatment trials for vascular dementia
Neuropsychology Post-Doctoral Fellows
Deborah Cahn-Weiner, Ph.D., 1996-98
Research Supervisor, Cognitive performance and functional status in normal aging and dementia (co-mentor with Dr. Malloy)
Current position-staff psychologist Memorial Hospital of RI
Lauren Norton, Ph.D., 1998-2000
Research Supervisor, Behavioral symptoms and activities of daily living in dementia (co-mentor with Dr. Malloy)
Current position staff psychologist Massachusetts General Hospital
Patricia Boyle, Ph.D., 2000-2002
Research supervisor, NIA F-32 Executive function and activities of daily living in Alzheimer's disease (co-mentor with Dr. Malloy)
Current position Director of Neuropsychology BU Alzheimer's Center
Stephen Correia, Ph.D., 2002-2005
Research supervisor, NIA T-32 Dementia Research Fellow
Diffusion tensor imaging of frontal systems in mild cognitive impairment. (co-mentor with Dr. Malloy)
Ryan Garrity, Ph.D., 2000-2002
Research supervisor, A trial of estrogens for prevention of Alzheimer's disease (co-mentor with Dr. Malloy) Current position-staff psychologist
Heather Belanger, Ph.D., 2002-2003
Research supervisor, Diffusion tensor imaging and executive function in Alzheimer's disease (co-mentor with Dr. Malloy)
Kelly Wilder-Willis, Ph.D., 2002-2004
Research supervisor, Working memory in Alzheimer's disease (co-mentor with Dr. Malloy)
Laura Frakey, Ph.D., 2005-2007
Research supervisor, Treatment of apathy in Alzheimer's disease with modafinil (co-mentor with Dr. Malloy)